Bepirovirsen (BEPI): A New Hope for Functional Cure in Hepatitis B

Welcome to a new season of podcasts from Dr. Robert Gish!

In this latest podcast, Dr. Robert Gish discusses bepirovirsen (BEPI), an antisense oligonucleotide in development for the treatment of chronic hepatitis B. He explains how BEPI targets hepatitis B viral RNA and why this emerging therapy could represent an important step beyond long-term nucleos(t)ide therapy.

Dr. Gish reviews key results from the B-Well 1 and B-Well 2 Phase 3 studies, including functional cure rates and the potential for finite therapy and treatment discontinuation in selected patients. He also highlights the importance of quantitative hepatitis B surface antigen (qHBsAg) in identifying patients who may benefit.

With new data showing substantially higher functional cure rates than those typically achieved with nucleos(t)ide analogues, BEPI could open new doors and bring new hope to the treatment of chronic hepatitis B.

Please feel free to send any questions or feedback to Dr. Gish via email rgish@robertgish.com or via his website www.robertgish.com 

Thank you for listening!